The product is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than EPO.
>99% by SDS-Page and HPLC analysis
<0.001 EU per 1 μg by the LAL method
Methoxy polyethylene glycol-epoetin beta
For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
Examples of Clinical Use:
Anaemia associated with chronic kidney disease
Stimulates hemoglobin production by stimulating the erythropoetin receptor of erythroid progenitor cells in the bone marrow. Hemoglobin increase, following a single initial dose, occurs 7 to 15 days after.
Mechanism of action:
Erythropoietin is a growth factor for erythroid development. It is produced in the kidney and released into the bloodstream in response to hypoxia, interacting with erythroid progenitor cells to increase red blood cell production. Production of endogenous erythropoietin is impaired in patients with chronic kidney disease (CKD), and erythropoietin deficiency is the primary cause of their anaemia. Administration of methoxy polyethylene glycol-epoetin beta acts like endogenous erythropoetin and stimulates erythropoetin receptor of the erythroid progenitor cells in the bone marrow.
The discovery and development of Methoxy polyethylene glycol-epoetin beta
Methoxy polyethylene glycol-epoetin beta (MPG-EPO) is a synthetic form of erythropoietin, a hormone that stimulates the production of red blood cells. It is used to treat anemia, particularly in patients with chronic kidney disease or cancer who are undergoing chemotherapy. The discovery and development of MPG-EPO involved several stages. Research into erythropoietin and its role in stimulating red blood cell production began in the mid-20th century. This led to the development of recombinant erythropoietin, a synthetic form of the hormone produced using genetic engineering techniques. In the 1990s, scientists began investigating the potential benefits of attaching polyethylene glycol (PEG) to erythropoietin molecules. PEGylation is a process that involves attaching PEG to a protein or peptide to improve its stability and prolong its circulation in the body. This can increase the half-life of the molecule, reducing the frequency of dosing required. The development of MPG-EPO involved extensive preclinical studies to assess its safety, efficacy, and pharmacokinetics. This was followed by clinical trials to evaluate its effectiveness in treating anemia in patients with chronic kidney disease and cancer. These trials provided valuable data on the optimal dosing, safety profile, and potential side effects of MPG-EPO. After demonstrating its safety and efficacy, MPG-EPO was submitted for regulatory approval, and it has since been approved for use in many countries around the world. The discovery and development of MPG-EPO represents a significant advancement in the treatment of anemia and has provided healthcare professionals with an important tool for managing this condition in patients with chronic illnesses.
The advantages and disadvantages of Methoxy polyethylene glycol-epoetin beta
Methoxy polyethylene glycol-epoetin beta, also known as Mircera, is a medication used to treat anemia in patients with chronic kidney disease and cancer. Some of the advantages of Methoxy polyethylene glycol-epoetin beta include: 1. Longer half-life: Methoxy polyethylene glycol-epoetin beta has a longer half-life compared to other erythropoiesis-stimulating agents (ESAs), which means it can be administered less frequently, often once a month. 2. Less frequent dosing: Due to its longer half-life, Methoxy polyethylene glycol-epoetin beta requires less frequent dosing compared to other ESAs, which can improve patient convenience and compliance. 3. Stable hemoglobin levels: Methoxy polyethylene glycol-epoetin beta has been shown to provide stable hemoglobin levels over an extended period, reducing the need for frequent dose adjustments. 4. Reduced healthcare resource utilization: The less frequent dosing of Methoxy polyethylene glycol-epoetin beta may lead to reduced healthcare resource utilization, such as fewer hospital visits for treatment. 5. Improved quality of life: By reducing the frequency of injections and stabilizing hemoglobin levels, Methoxy polyethylene glycol-epoetin beta may improve the quality of life for patients with anemia associated with chronic kidney disease and cancer. Methoxy polyethylene glycol-epoetin beta, like many medications, has potential disadvantages and side effects. Some of these may include: 1. Hypertension: Methoxy polyethylene glycol-epoetin beta can increase blood pressure in some individuals, leading to the potential development of hypertension. 2. Allergic reactions: Some people may experience allergic reactions to Methoxy polyethylene glycol-epoetin beta, which can range from mild to severe, including anaphylaxis. 3. Thromboembolic events: There is a risk of thromboembolic events, such as deep vein thrombosis and pulmonary embolism, associated with the use of Methoxy polyethylene glycol-epoetin beta. 4. Pure red cell aplasia: In some cases, the prolonged use of Methoxy polyethylene glycol-epoetin beta has been associated with the development of pure red cell aplasia, a condition characterized by the absence of red blood cell precursors in the bone marrow. 5. Bone marrow suppression: Methoxy polyethylene glycol-epoetin beta can lead to bone marrow suppression, resulting in decreased production of red blood cells, white blood cells, and platelets.
The medical application of Methoxy polyethylene glycol-epoetin beta
The medical application of Methoxy polyethylene glycol-epoetin beta is to increase the production of red blood cells, which helps to improve oxygen delivery to tissues and relieve symptoms of anemia such as fatigue and weakness. It is administered by injection and is typically given at regular intervals as prescribed by a healthcare professional. It's important to note that Methoxy polyethylene glycol-epoetin beta should only be used under the supervision of a healthcare provider and in accordance with the specific instructions for each patient's condition. Like all medications, it can have potential side effects and risks, so it's important to discuss the use of Methoxy polyethylene glycol-epoetin beta with a qualified healthcare professional.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.